Locally Advanced or Metastatic Solid Tumors
Precision Imaging.
Targeted Therapy.Measurable Outcomes.
Biogenix Molecular and CIRA Health are advancing clinical research in molecular imaging, theranostics, PET/CT, SPECT/CT, dosimetry, and targeted radiopharmaceutical therapy.
CIRA Health research infrastructureMolecular imaging, trial coordination, and theranostics workflow support.
Identify
Advanced PET imaging detects therapeutic targets including PSMA, SSTR, and GRPR.
Treat
Targeted radioligand therapy delivers focused radiation to cancer cells.
Track
Follow-up imaging supports response assessment and dosimetry-informed care.
Now Enrolling in Clinical Trials
Therapy Response Visualization
Pre-therapy and post-therapy molecular imaging shown for illustrative clinical research education.
786-791-1799Call to learn more
Coral Way Professional Center2760 SW 97th Avenue, Suite B103, Miami, FL 33165
About Biogenix Molecular
A CIRA Health Research Division
Biogenix Molecular is a clinical research division of CIRA Health dedicated to advancing molecular imaging and targeted radiopharmaceutical therapies through innovative clinical trials.
Our Mission
To improve patient outcomes by advancing precision imaging and targeted therapies through world-class research, physician collaboration, and compassionate care.
What We Do
Clinical Trials
Conducting phase 1-3 clinical trials across oncology and molecular imaging.
Theranostics
Combining diagnostic imaging with targeted radioligand therapy.
Patient Care
Collaborating with patients and physicians to improve outcomes.
Research
Advancing science to drive the future of precision medicine.
Our Commitment
We are committed to scientific excellence, patient safety, regulatory integrity, and data quality in every study we conduct.
Theranostics
The Power of Precision
Theranostics pairs molecular imaging with targeted radiopharmaceutical therapy, using the same biologic target to identify disease, deliver therapy, and monitor response over time.
TheranosticsThe Right Target.
The Right Therapy.
The Right Patient.
The Right Therapy.
The Right Patient.
1
IdentifyDetect targets with precision imaging2
TreatDeliver targeted radioligand therapy3
TrackMonitor response with follow-up imagingKey Molecular Targets
PSMA
Prostate Cancer
SSTR
Neuroendocrine Tumors
GRPR
Emerging Targets
The Theranostic Advantage
Personalized treatment based on your tumor biology
Targets cancer cells while minimizing damage to healthy tissue
Real-time monitoring of treatment response
Improved outcomes and quality of life
Molecular-based patient selection
Quantitative baseline disease burden
Clinical Response
Illustrative pre-treatment and post-treatment molecular imaging response.
Clinical Trials
Now Enrolling
Join a clinical trial and help advance the future of cancer care. Participation is voluntary, and not all patients will qualify.
For more information regarding clinical trial details, go to www.clinicaltrials.gov.
Clinical trials listed are research studies and involve investigational agents. Eligibility depends on prior treatments, imaging findings, and overall health.
Who may be eligible?Patients with prostate cancer, neuroendocrine tumors, or other advanced/metastatic solid tumors.
What is reviewed?Diagnosis, treatment history, prior imaging, and protocol-specific criteria.
Important informationParticipation is voluntary and there is no guarantee of benefit.
Clinical trial contactLina Osorio, RN
786-791-1799
losoriorn@cirahealth.com
786-791-1799
losoriorn@cirahealth.com
Metastatic Castration-Resistant Prostate Cancer
[225Ac]-AZD2284 in Patients with Metastatic Castration-Resistant Prostate Cancer
Lutetium (177Lu) rhPSMA-10.1 Injection
CLARIFY
Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT
A Phase 2 randomized, open-label dose-finding study of Debio 4228
To assess the safety and tolerability of LY4257496 monotherapy
Phase 1a/1b study to evaluate radioligand therapy with LY4337713 in adults
[203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors
Metastatic bone pain
Non-invasive detection of clear cell renal cell carcinoma (ccRCC)
Therapy for advanced SSTR2-positive neuroendocrine tumors
Request Clinical Trial Contact
Use this form to request a call from our research team about current clinical trial opportunities.
General Contact Only
Please do not include diagnosis, treatment history, imaging results, symptoms, medical records, or other medical information in this form.
Do not submit emergency medical concerns through this form. For emergencies, call 911. A member of our research team will contact you to discuss next steps through an appropriate process. For Netlify Forms, configure the form notification recipient as losoriorn@cirahealth.com.
For Referring
Physicians
We value our partnership with physicians and are here to support you and your patients through every step of the clinical trial process.
Referral & Coordination
Easy Referrals
Simple referral process with rapid contact coordination and study matching.
Collaborative Care
Referring physicians remain central to ongoing patient care.
Timely Communication
Updates on contact requests, imaging, protocol status, and patient progress.
Access to Innovation
Clinical trial access in molecular imaging and targeted radiopharmaceutical therapy.
Physician Hotline786-791-1799
Emailresearch@cirahealth.com
Clinical Trial ContactLina Osorio, RN · losoriorn@cirahealth.com
Ready to refer a patient?
Contact our research team or request contact.
Contact Us
We’re here to help.
Contact our research team for clinical trial contact requests, clinical trial questions, or physician referral coordination.
Phone
786-791-1799
research@cirahealth.com
losoriorn@cirahealth.com
Location
Coral Way Professional Center
2760 SW 97th Avenue, Suite B103
Miami, FL 33165
Hours
Monday – Friday
8:00 AM – 5:00 PM ET
Send a Message
Whether you are a patient, caregiver, or physician, our team is ready to assist you.
Get in Touch
Initial screening does not obligate participation. Study eligibility is determined by protocol criteria, physician review, and informed consent.
